Diamyd Medical AB (fra:DMN) Share Price

Company Profile

Business description
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company’s activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
Contact
Kungsgatan 29
StockholmSE-111 56
SWE
T: +46 86610026
https://www.diamyd.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 August 2026
Employees
41

Recommended

We’re no longer certain that software firms will outperform over the next decade, but positive outcomes remain possible for names like Salesforce.

Dan Romanoff, CPA | 09 March 2026

We believe AI weakens the competitive advantage of these companies.

Roy Van Keulen | 09 March 2026

Tech saw solid earnings, but there are more questions around which companies will benefit from AI, and which will be hurt.

Rachel Schlueter | 06 March 2026

Index	Last price	Change	% Change
All Ordinaries	8,823.60	16.90	-0.19%
CAC 40	7,924.61	68.88	-0.86%
DAX 40	23,444.93	146.10	-0.62%
Dow JONES (US)	47,094.14	407.41	-0.86%
FTSE 100	10,259.21	25.54	-0.25%
HKSE	25,408.46	348.83	-1.35%
NASDAQ	22,378.92	8.76	-0.04%
Nikkei 225	52,728.72	2,892.12	-5.20%
NZX 50 Index	13,098.83	519.06	-3.81%
S&P 500	6,710.64	29.38	-0.44%
S&P/ASX 200	8,599.00	3.30	-0.04%
SSE Composite Index	4,096.60	27.59	-0.67%